68 results about "Molecular entity" patented technology

Devices for detecting a transient electrical signal in a sample are provided. Also provided are systems that include the subject devices. The subject devices and systems find use in a variety of applications, particularly in the characterization of a sample, and more particularly in the characterization of molecular entities in the sample.

Systems and methods are described herein for disease knowledge modeling and clinical treatment decision support, and the prioritization of possible treatment options based on tumor or other disease biomarkers. Disease or indication information, including identification of biomolecular entities associated with the indication may be culled through text data mining to create a knowledge model of the indication. In some embodiments, the knowledge model may comprise a network of associations between molecular entities, including such drug targets and biomakers, genes, pathways. The model may be combined with patient-specific variant information and historical treatment records to identify and prioritize treatment decisions and allow for the prediction of disease drivers and provide treatment options tailored to a patient's genetic data.

The invention relates to novel hybrid compounds comprising at least one silicone entity (Sil) in which at least one of the silicons of Sil is substituted by at least one unit—Ro-B, B being an entity of a variable nature, for example polymer, hydrocarbonated or mineral, selected from a group comprising polyols (e.g. saccharides), silicones, polyalkylene glycols, polyamides, polyesters, polystyrenes, alkyls, alkenyls, alkynyls or aryls, in addition to mineral materials such as silica and the combinations thereof. The bond Ro between the entity Sil and the entity B is obtained by means of “click chemistry” and corresponds to formula (II.1) or (II.2), Z representing a carbon atom or a nitrogen atom. Said hybrid components can be used as emulsifiers, especially for cosmetics.

Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.

The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

A process for the absorption of one or more gas(es) selected from the group consisting of carbon dioxide, hydrogen sulfide, sulfur oxides, nitrogen oxides and carbon monoxide from a fluid, the process including: providing a fluid containing the selected gas(es); and an ionic liquid absorbent, the absorbent including the components: one or more anions; one or more metal species; and optionally one or more organic cations; and optionally one or more ligands; the absorbent components being selected such that the absorbent is in a liquid state at the operating temperature and pressure of the process; with the provisos that: when the anion contains in the same molecular entity: both an amine functional group and a sulfonate functional group; both an amine functional group and a carboxylate functional group; both a phosphine functional group and a sulfonate functional group; or both a phosphine functional group and a carboxylate functional group, the metal species is not an alkali metal or alkaline earth metal; the anion and / or metal species do not form a cuprate; and when the anion and / or metal species form a metal halide, the ionic liquid absorbent includes one or more ligands; contacting the fluid with the ionic liquid absorbent such that the selected gas(es) interact with the metal species; and collecting an ionic liquid in which at least a portion of the selected gas(es) is absorbed.

A process for the absorption of one or more gas(es) selected from the group consisting of carbon dioxide, hydrogen sulfide, sulfur oxides, nitrogen oxides and carbon monoxide from a fluid, the process including: providing a fluid containing the selected gas(es); and an ionic liquid absorbent, the absorbent including the components: one or more anions; one or more metal species; and optionally one or more organic cations; and optionally one or more ligands; the absorbent components being selected such that the absorbent is in a liquid state at the operating temperature and pressure of the process; with the provisos that: when the anion contains in the same molecular entity: both an amine functional group and a sulfonate functional group; both an amine functional group and a carboxylate functional group; both a phosphine functional group and a sulfonate functional group; or both a phosphine functional group and a carboxylate functional group, the metal species is not an alkali metal or alkaline earth metal; the anion and / or metal species do not form a cuprate; and when the anion and / or metal species form a metal halide, the ionic liquid absorbent includes one or more ligands; contacting the fluid with the ionic liquid absorbent such that the selected gas(es) interact with the metal species; and collecting an ionic liquid in which at least a portion of the selected gas(es) is absorbed.

The present invention is a one-step method for efficiently converting carbon-hydrogen bonds into carbon-carbon bonds using a combination of aryl halides, a substrate, and a copper salt as catalyst. This method allows faster introduction of complex molecular entities, a process that would otherwise require many more steps. This invention is particularly relevant for the organic synthesis of complex molecules such as, but not limited to, pharmacophores and explosives.

The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.

Pain associated with primary and secondary dysmenorrhea is relieved in a human suffering there from by administering to the human a pain relieving amount of a synergistically acting sub-therapeutic combination of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, magnesium, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, tramadol or its analog such as recemic tramadol or an analogously acting molecular entity or pharmaceutically acceptable salt thereof, and an anticonvulsant and / or a tricyclic anti-depressant or pharmaceutically acceptable salt thereof, and optionally in sustained release dosage form.

The present invention is of a molecular entity comprising a polypeptide core and nucleic acid sequences attached thereto which is capable of forming a universal logic gate such as the NAND gate. Specifically, the present invention can be used to device a molecular computing unit which can be used to detect biological markers and administer therapeutic moieties.

The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.

Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.

The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

The present disclosure describes systems and methods for predicting a likely side effect profile for even new, untested medications. A predicted side effect profile may be generated based on intersections of side effect profiles of other medications that affect the same or related molecular entities, such as the nearby target proteins, involve the same pathways, or are otherwise similarly related. To generate a predicted side effect profile for a new drug targeting a novel or previously un-targeted protein target, an analyzer may query an adverse event database for records pertaining to patients who have taken drugs or combinations of drugs that target or affect molecular entities in the vicinity of the novel target within a global molecular entity graph, and, in some embodiments, may retrieve a plurality of adverse event records and generate an intersection of side effects associated with related targets to predict likely side effects for the novel target.

Systems and methods are described herein for disease knowledge modeling and clinical treatment decision support. Disease or indication information, including identification of biomolecular entities associated with the indication may be culled through data mining to create a knowledge model of the indication. In some embodiments, the knowledge model may comprise a network of associations between molecular entities, including drug targets and biomarkers, genes, pathways. The model is used for prioritizing treatment decisions, for treatments comprising one or more medications associated with one or more molecular entities in the model. The priority of a suggested treatment depends on at least one property of one or more medications of the suggested treatment.

The invention provides chemical conjugates between an immunoglobulin Fab fragment and molecular entities imparting diagnostic or therapeutic utility, whereby the only sites of conjugation on the Fab fragment are one or both of the sulfhydryl groups deriving from the selective and quantitative reduction of the inter-chain disulfide bond of said Fab fragment and whereby said molecular entities imparting diagnostic or therapeutic utility have at least one free sulfhydryl-reactive group, characterized in that the conjugation stoichiometric molar ratio molecular entity to Fab fragment is in the range from 0.95 to 1.05 or in the range from 1.95 to 2.05. The invention also provides a process for preparing said conjugates and pharmaceutical compositions thereof.

An organized knowledge-supervised approach—Multidimensional Integrative eXpression Profiling (MIXP)—can not only improve sample classification accuracy by serving as a feature transformation approach, but also help in the discovery of groups of crucial molecular entities that have been too weak to detect individually through preexisting methods. Functionally related molecules that are individually expressed with low differentials, have often been considered as noise and ignored in traditional studies, but through the MIXP approach, they can be readily identified by virtue of their coordinate expression.

The present disclosure describes systems and methods for multivarlate analysis of adverse event data. According to a first aspect, patient-specific genomic Information is used to optimize or de-risk therapy for the patient. According to other aspects of the invention, unknown drug targets are identified via adverse event data. According to still other espects, a medication is identified to exclude from use for an indication or from a clinical trial of another medication. According to another aspect, a predicted side effect profile is generated for a medication targeting a novel target. According to still another aspect, combination therapies are identified via adverse event data. According to another aspect, molecular interactions between a plurality of molecular entities are displayed in an intuitive format. According to still another aspect, molecular entities responsible for adverse event differences between similar indications are identified. According to still another aspect, genetic variants associated with adverse events in a clinical trial are identified.

Methods, systems, devices and / or apparatuses are provided for computationally deriving molecular association connectivity maps for the study of inter-class molecular associations in toxicogenomics and drug discovery applications. The inter-class molecular associations can be between at least one bio-molecular entity and at least one therapeutic agent. The methods, systems, devices and / or apparatuses apply integrated molecular interaction network mining and text mining techniques.

The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

Provided are methods of collecting, detecting and altering cells and molecular entities using glycoprotein micelles and vesicles. Glycoprotein vesicles comprising a glycoprotein micelle, at least a monolayer of lectin and / or a monolayer of biologically active glycoproteins are also provided. The invention further provides methods of detecting protein glycosylation using the vesicles of the invention.

The invention relates to methods for separating and identifying DNA (deoxyribonucleic acid) binding protein, in particular to methods for separating and identifying DNA binding protein through a DNA co-immunoprecipitation technology. The separating method comprises the steps of extracting nucleoprotein of a cell, mixing a target DNA molecule and nucleoprotein, adding a molecular entity capable of being bound with the target DNA molecule, separating to obtain a nucleoprotein ingredient bound with the target DNA molecule, further separating the obtained nucleoprotein ingredient, and obtaining the DNA binding protein. The identifying method further comprises the step of identifying the DNA binding protein obtained by separating. The methods have the characteristics of good stability and repeatability, and significantly improve the experiment efficiency of identifying the unknown DNA binding protein. The methods provide beneficial help for subjects such as molecular behavioristics, molecular oncology, cytobiology and biochemistry deeply researching into cytogene transcriptional control and genetic transcription.

The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection.

The present invention provides systems and methods for determining enzymatic competency, which is important in determining whether a patient may suffer an adverse drug reaction, has a disease associated with defects in specific enzymatic function, and / or has an enzyme defect that is likely to cause pathophysiology. As contemplated herein, a parent molecular entity is administered to a patient in whom enzymatic competency is to be determined. A sample of the patient's bodily fluid is exposed to a sensor of the invention to distinguish, detect, and quantify a detectable entity in the bodily fluid. Sensor-acquired data regarding the detectable entity is used to determine enzymatic competency. Preferably, a sample of a patient's exhaled breath is collected and exposed to the sensor of the invention. Types of sensor systems of the invention include, but are not limited to, surface resonance arrays; microelectromechanical sensors (such as microcantilever-based technology); molecularly imprinted polymer sensors; amplifying fluorescent sensor technology; aptamer-based sensor technology; SAW sensors; infrared sensors; fuel cells; chemical reactors; and pH sensitive sensors.

The invention discloses a method for preparing 2-(4-((3S)-3-piperidyl) phenyl)-2H-indazole-7-formamide of a compound. Benzyl protected-piperidone is generated into piperidone of 3-triflic anhydride under the action of triflic anhydride, the piperidone and nitrobenzoic acid are subjected to Suzuki reaction to obtain a coupled product, 3-(4-aminophenyl) piperidine is obtained under the action of a palladium reagent, (S)-3-(4-halogenated phenyl) piperidine is prepared with a chirality resolution reagent, the (S)-3-(4-halogenated phenyl) piperidine is condensed with 3-formyl-2-methyl nitrobenzoate to form pyrazolone ring under the action of sodium azide, and the Niraparid (with the molecular entity of 2-(4-((3S)-3-piperidyl) phenyl)-2H-indazole-7-formamide) is prepared via aminolysis.

The invention relates to non-natural bases and base pairs that expand the normal DNA-based encoding system. Compositions herein may comprise at least one non-natural base that may interact with another base via a Watson Crick-type hydrogen bonding geometry and / or a Hoogsteen-type hydrogen bonding geometry. The bases may be used in a molecular entity, such as an oligomer or any other entity wherein the bases are attached to a backbone. For example, they may be comprised in DNA, RNA, or PNA, or a variety of other nucleic acid-type systems.

The invention relates to a compound drug carrier for multi-response mechanism and preparation method thereof. The compound drug carrier achieves three types of response mechanisms, exogenous stimulus magnetic fields, heat and endogenous stimulus pH, to regulate drug target release. The present invention provides a method to control drugs to release fixed concentration quantity drug in the target area within certain time. The method solves the problem of drug or medicine waste arising from traditional methods. The present invention alters the lowest solution temperature of polymer liquids through regulating the structure of molecular entity in the syntheses process of polymers. Through altering the temperature, the method regulates the physical characteristics of nanometer drug carrier to control the release of drug targets. FePt nanometer granule wrapped by polymers alters the polymer temperature through regulating the magnetic fields to cause the polymer to have phase transformation, to achieve the purpose of controlling drug releases. The nanometer carrier has superior cell compatibility, high cell intake rate and low cell toxic, and has wide application prospect in regulating the release of drug target and treating cancer diseases.

The present invention provides data analysis methods for the rapid location of subsets of large, multivariable biological datasets that are of most interest for further analysis, for the investigation of molecular modes of action of biological phenomena of interest, and for the identification of sets of data points that best distinguish between experimental groups in larger datasets as putative biomarkers. While existing methods for analyzing large biological datasets generally provide too much information to the user, or not enough, the methods of the present invention entail taking user input on what kinds of trends are of interest and then finding results that match the designated trend. In such manner, the methods of the invention allow a user to quickly pinpoint the subset of data of most interest without a concomitant loss of a large percentage of relevant information, as is typical with standard methods. The methods of the invention allow for identification of molecular entities that are involved in a biological phenomenon of interest, entities that may have otherwise gone undiscovered in a large, multivariable dataset.